The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction
Results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial
Craig M. Pratt, MD, FACC*,*,
Steven N. Singh, MD, FACC ,
Hussein R. Al-Khalidi, PhD ,
Jose M. Brum, MD,
Michael J. Holroyde, PhD,
Stephen R. Marcello, MD, FACC,
Peter J. Schwartz, MD, FACC ,
A. John Camm, MD, FACC|| ALIVE Investigators
* The Methodist DeBakey Heart Center and Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, Texas, USA
Department of Cardiology, Veterans Affairs Medical Center, Washington, DC, USA
Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, USA
Department of Cardiology, Policlinico S. Matteo, IRRCS and University of Pavia, Italy
|| Department of Cardiology, St. George's Hospital, London, United Kingdom
View larger version (14K):
[in a new window]
|
Figure 1 (A) All-cause mortality among atrial fibrillation (AF) patients versus patients not in AF at baseline. (B) Effect of AF on all-cause mortality adjusted for age, gender, hypertension, beta-blocker, angiotensin-converting enzyme inhibitors, ejection fraction, heart failure, diabetes, and New York Heart Association class. SR = sinus rhythm.
|
|
View larger version (20K):
[in a new window]
|
Figure 2 All-cause mortality among patients in atrial fibrillation at baseline. AZ = azimilide dihydrochloride.
|
|
View larger version (20K):
[in a new window]
|
Figure 3 Time-to-first documented atrial fibrillation among patients not in atrial fibrillation at baseline. AZ = azimilide dihydrochloride.
|
|
View larger version (20K):
[in a new window]
|
Figure 4 Time-to-first spontaneous conversion to sinus rhythm (SR) among patients in atrial fibrillation at baseline. AZ = azimilide dihydrochloride.
|
|
View larger version (49K):
[in a new window]
|
Figure 5 Prevalence of atrial fibrillation (Afib) at each visit: a follow-up of patients in Afib at baseline. Gray bars = placebo; black bars = 100 mg azimilide.
|
|
|
